This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View
by Zacks Equity Research
Centene's (CNC) fourth-quarter earnings were hurt by higher selling, general & administrative expenses.
Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View
by Zacks Equity Research
Anthem (ANTM) reported strong fourth-quarter results on the back of solid performance across its segments.
HCA Healthcare's (HCA) Q4 Earnings, Revenues Beat Estimates (Revised)
by Zacks Equity Research
HCA Healthcare's (HCA) strong fourth-quarter results were driven by significant growth in admissions.
MedTech Stock Q4 Earnings Slated for Jan 30: SYK, ZBH, ALGN
by Zacks Equity Research
The Medical sector is expected to stand out on favorable consumer behavior, growing prevalence of minimally-invasive surgeries, demand for liquid biopsy tests, and a value-based payment system.
Boston Scientific's (BSX) Millipede Deal Aids MR Business
by Zacks Equity Research
Boston Scientific (BSX) claims the Millipede IRIS annuloplasty ring to be highly customizable to a specific patient's anatomy and disease state.
Markets Keep Gaining Amid Strong Corporate Earnings
by Zacks Equity Research
Markets Keep Gaining Amid Strong Corporate Earnings
Plethora of Q4 Earnings Amid New Market Highs
by Mark Vickery
From GE and Comcast to United Technologies and General Dynamics, the latest round of Q4 earnings results is accounted for.
Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance
by Zacks Equity Research
Abbott (ABT) posts promising Q4 results on strong growth in all lines and expansion in emerging markets.
Abbott (ABT) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Abbott (ABT) rides high on new product approvals and launches in Q4.
This Week's Amazing Earnings Charts
by Tracey Ryniec
These 5 companies have consistently beat the earnings estimate. Will they do it again?
Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to gain on continued growth in Diagnostics business in Q4.
Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.
Abbott's (ABT) Diabetes Care Unit Strong on FreeStyle Libre
by Zacks Equity Research
Abbott (ABT) forges ahead with initiatives to boost diabetes care. The latest CMS recognition will widen customer base for FreeStyle Libre glucose monitoring system.
Abbott Boosts Diagnostics Arm With Alinity H-Series Launch
by Zacks Equity Research
Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.
The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum
Abbott (ABT) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Abbott's (ABT) successful closure of the Alere acquisition after a prolonged legal battle has boosted investor confidence.
Intersect ENT (XENT) SINUVA Implant Receives FDA Approval
by Zacks Equity Research
Intersect ENT's (XENT) consistent focus on the chronic sinusitis market is likely to lend the company a competitive edge in the niche space.
Global In Vitro Diagnostic Market Booms: Stocks in Focus
by Zacks Equity Research
With the emergence of complex and transmittable diseases worldwide, In Vitro Diagnostic within the MedTech space is currently in the spotlight.
DexCom-Lily Partnership to Boost CGM Platform, Customer Base
by Zacks Equity Research
DexCom (DXCM) continues to sign deals to boost CGM platform adoption.
HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View
by Zacks Equity Research
HCA Healthcare's (HCA) third quarter witnesses increase in revenues and admissions. However, expenses too escalate. The company reiterates guidance provided earlier this month.
Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Abiomed's (ABMD) strong performance in Impella heart pump boosted the company's second-quarter 2018 results.
Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues
by Zacks Equity Research
Integra LifeSciences' (IART) raised full-year 2017 revenue guidance buoys optimism.
Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales
by Zacks Equity Research
An extremely strong summer teen season drives Align Technology's (ALGN) Invisalign growth within the global teen market in the third quarter.
Chemed (CHE) Beats on Q3 Earnings & Revenues, View Revised
by Zacks Equity Research
Chemed (CHE) rides high on its Roto-Rooter business in Q3
ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines
by Zacks Equity Research
ResMed (RMD) delivers a promising Q1 on the back of solid contributions from domestic and international businesses.